Bone
01 Jan 2013
Ibandronic Acid versus Zoledronic Acid in Cancer Patients with Skeletal Metastases Experiencing Moderate to Severe Pain
The purpose of the study is to investigate a new therapy for treating bone pain that results from cancer that has spread to the bones. The study compares treatment with ibandronic acid against treatment with another drug, zoledronic acid (a drug similar to ibandronic acid) to determine which drug is…
Hormones
01 Jan 2013
Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients with Thyroid or Pituitary Abnormalities
This study will determine the safety and activity of a new formulation of thyrotropin-releasing hormone (TRH), a drug used for diagnosing and evaluating patients with certain thyroid gland abnormalities. Normal thyroid gland function depends on proper chemical signaling between the thyroid gland, the hypothalamus (the part of the brain where…
Cancer
01 Jan 2013
Celecoxib in Managing Pain, Weight Loss, and Weakness in Patients With Advanced Cancer
RATIONALE: Celecoxib may help relieve moderate or severe pain associated with cancer. It may also decrease weight loss and improve muscle strength in cancer patients. PURPOSE: Randomized clinical trial to study the effectiveness of celecoxib in managing pain, weight loss, and weakness in patients with advanced cancer. Official Title…
Blood
01 Jan 2013
SR34006 Compared to Placebo in Patients who have Completed 6 Months of Treatment for Symptomatic Pulmonary Embolism or Deep Vein Thrombosis
Patients diagnosed with pulmonary embolism (blood clot in the lung) or deep vein thrombosis (blood clot in a leg vein) are at risk for these blood clots to reoccur. Anticoagulant (blood-thinning) drugs are normally given immediately after the clot is discovered and are continued for a period of 3 or…
Cancer
01 Jan 2013
Maintenance ZD1839 (IRESSA®) Following Completion of Front Line, Platinum-Based, Double Chemotherapy in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer
In this Phase IIIb, randomized, double-blind, maintenance study, 300 subjects with advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) (Stage IIIB {T4-pleural effusion} and IV) who have SD or objective tumor response immediately following the completion of 4-6 cycles of front line, platinum-based, doublet chemotherapy will be randomized in a…
Bone
01 Jan 2013
Study Compares Treatments for Women with Postmenopausal Osteoporosis
Once-weekly alendronate 70 mg and once-weekly risedronate 35 mg are indicated for the treatment of postmenopausal osteoporosis. These two agents were compared in a 12-month head-to-head trial. Greater gains in BMD and greater reductions in markers of bone turnover were seen with alendronate compared with risedronate with similar tolerability.
Children's health
01 Jan 2013
Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Children and Adolescent Patients with Bipolar I Mania
The purpose of this study is to demonstrate efficacy and safety of quetiapine fumarate (SEROQUEL) compared with placebo in the treatment of children and adolescent patients with Bipolar I mania. Official Title Conditions Bipolar Disorder Study Type Interventional Study Design Treatment, Placebo Control, Safety/Efficacy Study Further Details Study Start…
Cancer
01 Jan 2013
Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-small Cell Lung Cancer (NSCLC)
The purpose of this study is to compare combination treatment of gemcitabine + oxaliplatin (GEMOX) with carboplatin + paclitaxel (CP) to determine if there is a difference in response and safety between the two drug combinations for the treatment of advanced non-small cell lung cancer (NSCLC). Official Title A Phase…
Cancer
01 Jan 2013
FASLODEX and AROMASIN in Hormone Receptor Positive Postmenopausal Women with Advanced Breast Cancer
The purpose of this study is to compare the efficacy of Faslodex (fulvestrant) to Aromasin (exemestane) in hormone receptor positive postmenopausal women with advanced breast cancer. Patients will be treated until disease progression or until the investigator has determined that treatment is not in the best interest of the patient,…
